Skip to content
value.today

NeuroOne Medical Technologies Corporation

NMTC
$8 Mmarket cap on Oct 30, 2026-77.8% since Jan 2024
Compare
World rank
#26,176
Revenue
$9 M
For year ending September-2025
Net income
$-4 M
-39.7% margin
SEC filing
Employees
18
As of September 30, 2025
SEC filing

NeuroOne Medical Technologies Corporation in brief

NeuroOne Medical Technologies Corporation is a listed company in the Medical Devices industry, based in Eden Prairie, Minnesota, USA. Its market value was $8 M on 30 October 2026, which makes it the 26,176th largest listed company in the world and the 4,334th largest in the USA on this site. In the year to September 2025 it had sales of $9 M and a net loss of $4 M. It employs about 18 people and David A. Rosa is its chief executive. Its largest product and service lines by sales in 2025 were OneRF Ablation System Revenue (100%). Its shares trade under the symbol NMTC (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About NeuroOne Medical Technologies Corporation

We are a medical technology company focused on (i) diagnostic, ablation and deep brain stimulation technology for brain related conditions such as epilepsy and Parkinson’s disease; (ii) ablation and stimulation for pain management throughout the body; and (iii) drug delivery including diagnostic and stimulation capabilities.

We have received 510(k) clearance for four of our devices from the Food and Drug Administration, including: (i) our Evo cortical electrode technology for temporary (less than 30 days) recording, monitoring, and stimulation on the surface of the brain, (ii) our Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, (iii) our OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures, and (iv) our OneRF TN ablation system for use in procedures to create radiofrequency lesions for the treatment of pain, or for lesioning nerve tissue for functional neurosurgical procedures. We have a distribution agreement with Zimmer, Inc. providing Zimmer Biomet Holdings, Inc. with a license to commercialize and distribute the Evo Cortical, Evo sEEG, and OneRF Brain Ablation System in the brain. We initiated a limited market release of the OneRF TN Ablation System in December 2025. The Company’s other products and indications are still under development.

From the company's annual report filed with the US SEC: read the report

NeuroOne Medical Technologies Corporation timeline

3 events, 2010–2025
  1. 2010
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2017
  4. ✎
    Renamed NEUROONE MEDICAL TECHNOLOGIES Corp
    Formerly Original Source Entertainment, Inc..
  5. 2025
  6. 💰
    Record revenue of $9 million
    FY2025, the highest of the 5 years on record.

Events of NeuroOne Medical Technologies Corporation from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$12 M$23 M$35 M$46 M2020202120222023202420252026

World rank over time

▼ down 2,854 places since 2020
2020-01-01: #23330#23,33020202021-01-01: #21701#21,70120212022-01-07: #28955#28,95520222022-12-25: #28455#28,45520222023-07-30: #29753#29,75320232024-01-05: #26256#26,25620242026-03-08: #11138#11,13820262026-08-01: #22125#22,12520262026-10-14: #25986#25,98620262026-10-30: #26184#26,1842026

Rank in USA: #4,290 (Jan 2020) · #4,207 (Jan 2021) · #5,158 (Jan 2022) · #5,174 (Dec 2022) · #5,223 (Jul 2023) · #4,179 (Jan 2024) · #2,167 (Mar 2026) · #3,968 (Aug 2026) · #4,265 (Oct 2026) · #4,337 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.9×
Price / book
1.2×
Free cash flow yield
-34.6%
Net margin (TTM)
-78.9%
Operating margin
-46.5%
Return on equity
-105.5%
Liabilities / assets
34.4%
Revenue growth
+163.8%
R&D / revenue
54.7%
Revenue per employee
$506 K
Profit per employee
$-201 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2016: revenue —, net income $-0M—FY16Fiscal year ending Sep 2019: revenue —, net income $-7M—FY19Fiscal year ending Sep 2020: revenue —, net income $-14M—FY20Fiscal year ending Sep 2021: revenue $0M, net income $-10M$0MFY21Fiscal year ending Sep 2022: revenue $0M, net income $-10M$0MFY22Fiscal year ending Sep 2023: revenue $2M, net income $-12M$2MFY23Fiscal year ending Sep 2024: revenue $3M, net income $-12M$3MFY24Fiscal year ending Sep 2025: revenue $9M, net income $-4M$9MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Sep 2025$9M+163.8%$-4M$-4M-39.7%
Sep 2024$3M+76.9%$-12M$-12M-357.1%
Sep 2023$2M+1047.1%$-12M$-12M-608.2%
Sep 2022$0M-5.6%$-10M$-10M-5882.4%
Sep 2021$0M—$-10M$-10M-5527.8%
Sep 2020——$-5M$-14M—
Sep 2019——$-6M$-7M—
Dec 2016——$-0M$-0M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Sep 2025$-3M$0M$-3M$-0.09—
Sep 2024$-11M$0M$-11M$-0.46—
Sep 2023$-13M$0M$-13M$-0.65—
Sep 2022$-8M$0M$-8M$-0.63—
Sep 2021$-9M$0M$-9M$-0.93—
Sep 2020$-3M$0M$-4M$-2.52—
Sep 2019$-5M$0M$-5M$-0.57—
Dec 2016$-0M——$-0.01—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$9M
Net income, trailing 12 months
$-7M
RevenueNet income
Three months to Sep 2024 (from the annual report): revenue $0M, net income $-3M$0MSep ’24Three months to Dec 2024: revenue $3M, net income $2M$3MDec ’24Three months to Mar 2025: revenue $1M, net income $-2M$1MMar ’25Three months to Jun 2025: revenue $2M, net income $-2M$2MJun ’25Three months to Sep 2025 (from the annual report): revenue $3M, net income $-2M$3MSep ’25Three months to Dec 2025: revenue $3M, net income $-1M$3MDec ’25Three months to Mar 2026: revenue $2M, net income $-2M$2MMar ’26Three months to Jun 2026: revenue $2M, net income $-2M$2MJun ’26

Latest quarter to Jun 2026: revenue $2M (+15.9% on a year earlier), net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of NeuroOne Medical Technologies Corporation with the US Securities and Exchange Commission.

Annual results

Revenue
$9 M
Operating income
$-4 M
Net income
$-4 M

For year ending September-2025 · source: SEC filing

Balance sheet

Total assets
$11 M
Total liabilities
$4 M
Total equity
$7 M

As of September-2025

Top 22 institutional investors in NeuroOne Medical Technologies Corporation#

As of Sep 30, 2026
22 institutions held 1.6 M shares (about 18.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 17.5%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 22 largest institutional investors in NeuroOne Medical Technologies Corporation
#InstitutionShares heldChange (shares)% heldValueFiled
1Bleichroeder LP666,6660 (0.00%)7.66%$1 MNov 13, 2026
2Vanguard Capital Management LLC352,150-624 (-0.18%)4.05%$0 MNov 13, 2026
3Perkins Capital Management Inc159,854-84,802 (-34.66%)1.84%$0 MNov 2, 2026
4Geode Capital Management, LLC93,5550 (0.00%)1.07%$0 MNov 6, 2026
5Sio Capital Management, LLC82,7670 (0.00%)0.95%$0 MNov 16, 2026
6Vanguard Fiduciary Trust Co49,0180 (0.00%)0.56%$0 MNov 13, 2026
7State Street Corp43,015New0.49%$0 MNov 12, 2026
8Cambridge Investment Research Advisors, Inc.28,715-28,283 (-49.62%)0.33%$0 MNov 2, 2026
9BlackRock, Inc.24,029-1,092 (-4.35%)0.28%$0 MNov 13, 2026
10Northern Trust Corp21,3980 (0.00%)0.25%$0 MNov 16, 2026
11Two Sigma Securities, LLC19,881New0.23%$0 MNov 16, 2026
12Barclays PLC18,757+18,681 (+24580.26%)0.22%$0 MNov 6, 2026
13UBS Group AG14,264+11,641 (+443.80%)0.16%$0 MNov 10, 2026
14Belpointe Asset Management LLC12,5000 (0.00%)0.14%$0 MNov 9, 2026
15Morgan Stanley1,835-223 (-10.84%)0.02%$0 MNov 13, 2026
16Tower Research Capital LLC (TRC)1,283+1,171 (+1045.54%)0.01%$0 MNov 16, 2026
17GK Wealth Management LLC692New0.01%$0 MOct 9, 2026
18Royal Bank Of Canada312New0.00%$0 MNov 16, 2026
19Wells Fargo & Company/mn1660 (0.00%)0.00%$0 MNov 16, 2026
20Jpmorgan Chase & Co88New0.00%$0 MNov 12, 2026
21Osaic Holdings, Inc.580 (0.00%)0.00%$0 MNov 12, 2026
22SBI Securities Co., Ltd.130 (0.00%)0.00%$0 MOct 22, 2026

Mutual funds holding NeuroOne Medical Technologies Corporation#

9 funds hold shares worth $1 M (about 5.3% of the company). Since their previous reports 9 added shares and 0 sold, buying $1 M net.
Mutual funds holding NeuroOne Medical Technologies Corporation
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.254,938$1 M2.9%<0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.90,120$0 M1.0%<0.01%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC49,310$0 M0.57%<0.01%newMay 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors23,642$0 M0.27%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC13,914$0 M0.16%<0.01%newMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC11,879$0 M0.14%<0.01%newMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.7,716$0 M0.09%<0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC4,972$0 M0.06%<0.01%newMay 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC1,479$0 M0.02%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 9 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at NeuroOne Medical Technologies Corporation#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$737 K
2 purchases, 1 insider
Sold, 12 months
$55 K
6 sales, 1 insider
Net, 12 months
$682 K
open market only
Insiders on file
15
since
$670 K-$72 K$0Dec 2023: bought $105 K (1 trades), sold $72 K (4 trades)Dec 23Jun 2024: bought $0 (0 trades), sold $25 K (2 trades)Apr 2025: bought $150 K (2 trades), sold $0 (0 trades)AprMay 2025: bought $0 (0 trades), sold $13 K (4 trades)Jun 2025: bought $0 (0 trades), sold $6 K (1 trades)JunSep 2025: bought $0 (0 trades), sold $22 K (1 trades)Mar 2026: bought $670 K (1 trades), sold $23 K (5 trades)MarJun 2026: bought $0 (0 trades), sold $32 K (1 trades)Aug 2026: bought $67 K (1 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
NeuroOne Medical Technologies Corporation: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed David J. WambekeChief Business OfficerBuy+33,333$2.010$67 K199,999Form 4
filed Mark ChristiansonMarket Development DirectorSell-10,000$3.180$32 K20,692Form 4
filed Edward AndrleDirectorGrant or award+41,929——133,932Form 4
filed Jeffrey S. MathiesenDirectorGrant or award+41,929——156,343Form 4
filed Jason Richard MillsDirectorGrant or award+41,929——49,687Form 4
filed Paul BuckmanDirectorGrant or award+41,929——178,733Form 4
filed David A. RosaCEO and President, DirectorShares withheld for tax-2,458$0.780$2 K1.08 MForm 4
filed Steve MertensChief Technology OfficerShares withheld for tax-906$0.780$707152,141Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: NeuroOne Medical Technologies Corporation#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
207,063
2.5% of shares · 2.39 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-08-27 13:34 UTC, code LUDP, resumed 13:44 UTC
  • 2026-04-15 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 817 shares at $0.97
  • : 1,089 shares at $0.86
  • : 1,189 shares at $0.85
  • : 1,089 shares at $0.80
  • : 412 shares at $0.92

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

NeuroOne Medical Technologies Corporation scorecard#

Passes 8 of the 19 checks that could be worked out: strongest in growth (4 of 5), weakest in profitability (1 of 5). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.2×Price to book 1.2× against Medical Devices's median of 2.5×.
    • ✓Price to sales below its peers' median0.9×Price to sales 0.9× against Medical Devices's median of 2.4×.
    • ✗Free cash flow yield above 5%-34.6%Free cash flow is -34.6% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 5
    • ✓Revenue grew in the newest year163.8%Revenue up 163.8% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years276.9%276.9% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median276.9%276.9% a year against Medical Devices's median of 10.8% (73 companies).
    • ✗Earnings per share grew in the newest year-0.09 vs -0.46Diluted EPS -0.09 in fiscal 2025 against -0.46 the year before (report's currency).
    • ✓Net income higher than five years earlier-$4 M-$4 M in fiscal 2025 against -$14 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$4 MNet income -$4 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-46.5%-46.5% against Medical Devices's median of -8.2% (86 companies).
    • ✗Return on equity above 15%-91.5%-91.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-46.5%-46.5% in fiscal 2025 against -5900.0% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities4.5×Current ratio 4.45 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-8.40Z-score -8.40 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year50.0%Diluted shares up 50.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from NeuroOne Medical Technologies Corporation's statements, beside the median of Medical Devices.

NeuroOne Medical Technologies Corporation: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-46.5%-8.2%
Net margin-39.7%-10.4%
Return on equity-91.5%-16.8%
Revenue growth, 3 years a year276.9%10.8%
Revenue growth163.8%10.4%
Free cash flow margin-32.1%-1.9%

6of 8on the Piotroski tests of financial strength

  • Net loss of $4 million, the 7th loss-making year in a row.
  • Free cash flow was negative: -$3 million.
  • The share count rose 50.0% in the year.
  • Receivables grew 600% while revenue grew 164%: customers are paying later, or sales were booked ahead of cash.

NeuroOne Medical Technologies Corporation: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

NeuroOne Medical Technologies Corporation: statements by fiscal year
PeriodTrendFY 2025to Sep 30, 2025FY 2024to Sep 30, 2024FY 2023to Sep 30, 2023FY 2022to Sep 30, 2022FY 2021to Sep 30, 2021FY 2020to Sep 30, 2020FY 2019to Sep 30, 2019FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015
Income statement
Revenue9,0983,4531,952171178———00r
Cost of revenue3,9562,3731,496242276—————
Gross profit5,1411,080457−71−98—————
Research and development4,9835,0656,9414,9293,9252,0761,529———
Selling, general and administrative7,3857,9026,9266,9796,260—————
Selling and marketing0.7619————————
General and administrative5,8486,498——6,2604,7534,284—3331r
Operating expenses12,36812,96713,86711,90910,1856,8295,813—3331r
Operating income−4,226−11,887−11,955−10,031−10,218−4,902−5,813—−33−31r
Interest expense and finance costs————3.1——35—14
Net interest income————−3.1−7,525−285———
Other non-operating income (expense)—1259631——————
Income before tax−3,605−12,318−11,859−10,000—−2,018——−33−31r
Income tax————−271———00
Income from continuing operations————————−33−31
Income from discontinued operations————————−16−17
Net income including minority interests————−9,948−13,640−6,781———
Net income attributable to shareholders−3,605−12,318−11,859−10,000−9,948−13,640−6,781—−48−63
Earnings per share, basic-0.09-0.46-0.65-0.63-0.93-2.52r-0.57—-0.01-0.01
Earnings per share, diluted-0.09-0.46-0.65-0.63-0.93-2.52r-0.57—-0.01-0.01
Shares, weighted average (basic)4027181611—————
Shares, weighted average (diluted)40271816115.4r12—5.15.1
Balance sheet
Cash and cash equivalents6,5701,4605,3228,1606,9014,03626126522r0r
Short-term investments———2,981——————
Receivables1,265177—3348————0
Inventory2,2272,6351,72770598—————
Other current assets—216264———————
Current assets10,2264,6317,31312,1767,2924,155302345761.8
Property, plant and equipment25941752635422316652———
Right-of-use (leased) assets255255169181289282————
Other intangible assets456790112134157179216181—
Total assets10,7865,3708,09712,8237,9384,760533250757r1.8
Accounts payable1,0101,0296859285297631,152—2211r
Current liabilities2,3032,2131,7933,0991,1822,3561,7703,905677r83
Long-term debt——55120203254————
Lease liabilities (non-current)14319455120203254————
Total liabilities3,7134,5481,8483,2181,3852,6941,7705,2871,023r83
Retained earnings−78,610−75,004−62,686−50,827−40,827−30,879−17,239−5,325−266r−180
Shareholders' equity7,0738226,2499,6046,5542,066−1,238−5,037−266r−81
Total liabilities and equity10,7865,3708,09712,8237,9384,760533250757r1.8
Shares outstanding8.3r312416127.4r137.95.2r5.1
Cash-flow statement
Depreciation and amortization262247199119814828———
Share-based compensation1,2651,3441,1059471,7931,83632477——
Cash from operating activities−2,837−11,012−12,887−7,520−8,603−3,425−5,396—−21−30r
Capital expenditure−82−120−384−275−67−122−58———
Intangible assets bought——————−65———
Cash from investing activities−82−1202,650−3,245−67−122−123—00
Shares issued—837r2,553———————
Cash from financing activities8,0297,2707,39912,02311,5357,3235,767—2130r
Change in cash————2,8653,776————
Report10-K10-K10-K10-K10-K10-K/A10-K10-Q10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What NeuroOne Medical Technologies Corporation sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • OneRF Ablation System Revenue$9 M100%

Source: SEC annual report (XBRL data) · as of Sep 30, 2025

Executive pay at NeuroOne Medical Technologies Corporation#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.2 M
Mr. Rosa
Other top executives, average
$606 K
the CEO earned 1.9× this
$100 invested is now
$53
NeuroOne Medical Technologies Corporation: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Mr. Rosa$1.2 M$1.3 M$606 K$53
2024David A. Rosa$2.0 M$1.9 M$655 K$59
2023David A. Rosa$990 K$716 K$424 K$53

Source: SEC proxy statement (Form DEF 14A) · as of Sep 30, 2025

Events at NeuroOne Medical Technologies Corporation#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Financial statements withdrawnFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Financial statements withdrawn 1 · Directors and officers 4 · Material agreement 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 10

NeuroOne Medical Technologies Corporation: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Financial statements withdrawn8-K
Results announced8-K
Directors and officers8-K
Bylaws or fiscal year changed8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Results announced8-K
Results announced8-K
Delisting notice8-K
Material agreement8-K
Directors and officersShareholder vote8-K/A
Shareholder vote8-K
Results announced8-K
Results announced8-K
Delisting notice8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 5, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of NeuroOne Medical Technologies Corporation
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2021$13 MPrivate placement after listing$10 to $50 million36equity, optionsSEC
Apr 2020$2 MPrivate placement after listing$2 to $10 million33equity, debt, optionsSEC
Nov 2019$1 MPrivate placement after listingUnder $2 million16equity, debt, optionsSEC
Jul 2018$2 MPrivate placement after listingUnder $2 million21equity, optionsSEC
Oct 2017$1 MPrivate placement after listingUnder $2 million20debt, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How NeuroOne Medical Technologies Corporation compares in Medical Devices

  • Market cap$8 M · higher than 4% of 142
  • Revenue$9 M · higher than 16% of 155
  • Net margin-78.9% · higher than 19% of 144
  • Revenue growth163.8% · higher than 98% of 104
  • Price / sales0.9× · lower than 87% of 96
  • Price / book1.2× · lower than 84% of 99
  • FCF yield-34.6% · higher than 23% of 76

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
NeuroOne Medical Technologies Corporation🇺🇸$8 M—-78.9%+163.8%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending September-2025
Balance sheet:
As of September-2025
Employees:
As of September 30, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at NeuroOne Medical Technologies Corporation? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show NeuroOne Medical Technologies Corporation's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about NeuroOne Medical Technologies Corporation? Suggest a correction